Derek Lowe (chemist)

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Derek Lowe is a medicinal chemist working on preclinical drug discovery in the pharmaceutical industry, and has written a blog about his field called "In the Pipeline" since 2002.[1]

Lowe (born in Harrisburg, Arkansas) got his BA from Hendrix College and his PhD in organic chemistry from Duke University on synthesis of natural products, before spending time in Germany on a Humboldt Fellowship.[2][3]

Lowe was the one of the first people to blog from inside the pharmaceutical industry (he talked to his supervisor and the company legal department before starting),[4] and one of the first science bloggers.[5] By 2006, his blog had between 3,000 and 4,000 visitors per day during the workweek; he covered business matters, trends and issues in medicinal chemistry, and legal matters like patent law and regulation.[6] At that time he was working at a pharmaceutical chemistry doing hit to lead medical chemistry work.[6] As of 2010 his blog received between 15,000 and 20,000 page views on a typical weekday.[7] His response to a 2013 article in Buzzfeed that propagated chemophobia was widely cited.[8][9][10]

He serves on the editorial board of ACS Medicinal Chemistry Letters and on the advisory board of Chemical & Engineering News.[11]

As of 2018 he was working at Novartis; formerly he had worked for 10 years at Vertex, 9 years at Bayer, and 8 years at Schering-Plough.[3][12][13]

Book
  • Lowe, Derek B. (2016). The Chemistry Book: From Gunpowder to Graphene, 250 Milestones in the History of Chemistry. Sterling. ISBN 9781454911807.
Selected scientific papers
  • Greenlee, W; Clader, J; et al. (April 2001). "Muscarinic agonists and antagonists in the treatment of Alzheimer's disease". Farmaco (Societa chimica italiana : 1989). 56 (4): 247–50. PMID 11421251.
  • Lowe, DB; Magnuson, S; et al. (21 June 2004). "In vitro SAR of (5-(2H)-isoxazolonyl) ureas, potent inhibitors of hormone-sensitive lipase". Bioorganic & Medicinal Chemistry Letters. 14 (12): 3155–9. doi:10.1016/j.bmcl.2004.04.015. PMID 15149665.
  • Rudolph, J; Esler, WP; et al. (18 October 2007). "Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity". Journal of Medicinal Chemistry. 50 (21): 5202–16. doi:10.1021/jm070071+. PMID 17887659.
  • Arrowsmith, CH; Audia, JE; et al. (August 2015). "The promise and peril of chemical probes". Nature Chemical Biology. 11 (8): 536–41. doi:10.1038/nchembio.1867. PMC 4706458. PMID 26196764.
Selected blogs or commentary

References[edit]

  1. ^ Weintraub, Karen (5 March 2016). "Derek Lowe: Chemist puts a human face on drug development". STAT.
  2. ^ "Odyssey Medal: Derek Lowe". Hendrix College. 2014.
  3. ^ a b "Derek Lowe". LinkedIn. Retrieved 29 May 2018.
  4. ^ Secko, David (August 2005). "The Power of the Blog". The Scientist. Archived from the original on 2011-05-14.
  5. ^ "The oldest science blog of all? | Gene Expression | Discover Magazine". Blogs.discovermagazine.com. 2010-08-24. Retrieved 2012-02-22.
  6. ^ a b Raber, Linda R. (June 19, 2006). "Moving Away From Target-Based Discovery". Chemical & Engineering News.
  7. ^ Jarvis, Lisa (24 August 2010). "Pharma Blogging Panel at ACS Boston". The Haystack.
  8. ^ "Foods Ingredients Banned Outside the US". ABC News. 26 June 2013.
  9. ^ Nosowitz, Dan (June 21, 2013). "Chemist Says BuzzFeeᴅ Article About Food Chemistry Has "Serial Stupidities"". Popular Science.
  10. ^ Jogalekar, Ashutosh (July 11, 2013). "Where's the chemistry lobby? On why we need a National Center for Chemical Education". Scientific American Blog Network.
  11. ^ Baum, Rudy M. (3 May 2010). "C&EN In The Blogosphere". Chemical & Engineering News. 88 (18): 3. doi:10.1021/cen-v088n018.p003.
  12. ^ Lieu, Chris (28 March 2017). "BioCentury - Lowe parts ways with Vertex amid reorganization". Biocentury.
  13. ^ Chemjobber (November 20, 2017). "Layoffs and the midcareer chemist". Chemical & Engineering News. 95 (46).

External links[edit]